Breast Cancer Research

(ISSN: 1465-5411,1465-542X)

Articles Available on Medscape


Table of Contents

From Breast Cancer Research

2019 - 21 (1)

  • Rack1 mediates tyrosine phosphorylation of Anxa2 by Src and promotes invasion and metastasis in drug-resistant breast cancer cells. 
  • Blood DNA methylation and breast cancer risk: a meta-analysis of four prospective cohort studies. 
  • Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications. 
  • Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo. 
  • Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization. 
  • Glutamine to proline conversion is associated with response to glutaminase inhibition in breast cancer. 
  • Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. 
  • Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. 
  • Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer. 
  • Parity predisposes breasts to the oncogenic action of PAPP-A and activation of the collagen receptor DDR2. 
  • Distant metastasis dynamics following subsequent surgeries after primary breast cancer removal. 
  • The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer. 
  • Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. 
  • The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells. 
  • Regular use of aspirin and other non-steroidal anti-inflammatory drugs and breast cancer risk for women at familial or genetic risk: a cohort study. 
  • BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. 
  • Association between prediagnostic leukocyte telomere length and breast cancer risk: the Singapore Chinese Health Study. 
  • The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. 
  • Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype. 
  • CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough? 
  • Genomic signature of parity in the breast of premenopausal women. 
  • Correction to: ECM1 regulates cell proliferation and trastuzumab resistance through activation of EGF-signaling. 
  • Hypothyroidism and the risk of breast cancer recurrence and all-cause mortality - a Danish population-based study. 
  • Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancer. 
  • Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. 
  • A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling. 
  • Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). 
  • Serum erythropoietin levels, breast cancer and breast cancer-initiating cells. 
  • Letter to the Editor: A response to Hruska's case study on molecular breast imaging and the need for true tissue quantification. 
  • The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. 
  • The distribution and determinants of mammographic density measures in Western Australian aboriginal women. 
  • Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial. 
  • Osteoblasts are "educated" by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. 
  • Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier. 
  • p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling. 
  • Intravital imaging reveals systemic ezrin inhibition impedes cancer cell migration and lymph node metastasis in breast cancer. 
  • Methylglyoxal, a glycolysis metabolite, triggers metastasis through MEK/ERK/SMAD1 pathway activation in breast cancer. 
  • Localized mammographic density is associated with interval cancer and large breast cancer: a nested case-control study. 
  • Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model. 
  • HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer. 
  • Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression. 
  • MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer. 
  • Correction to: Targeted therapy against Bcl-2-related proteins in breast cancer cells. 
  • Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3β activities. 
  • Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. 
  • Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain. 
  • Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. 
  • Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. 
  • Impact of obesity on breast cancer recurrence and minimal residual disease. 
  • Airborne metals and polycyclic aromatic hydrocarbons in relation to mammographic breast density. 
  • Parity, breastfeeding, and breast cancer risk by hormone receptor status and molecular phenotype: results from the Nurses' Health Studies. 
  • CXCL17-derived CD11b+Gr-1+ myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB. 
  • PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. 
  • Impact of short-term low-dose tamoxifen on molecular breast imaging background parenchymal uptake: a pilot study. 
  • Targeted mutation detection in breast cancer using MammaSeq™. 
  • GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer. 
  • Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours. 
  • Separation of breast cancer and organ microenvironment transcriptomes in metastases. 
  • Exosomal miRNA profile as complementary tool in the diagnostic and prediction of treatment response in localized breast cancer under neoadjuvant chemotherapy. 
  • A method of producing genetically manipulated mouse mammary gland. 
  • Updating the role of obesity and cholesterol in breast cancer. 
  • MiR-1287-5p inhibits triple negative breast cancer growth by interaction with phosphoinositide 3-kinase CB, thereby sensitizing cells for PI3Kinase inhibitors. 

Journal Information

Mission Statement: Breast Cancer Research is a multidisciplinary journal edited by Bruce Ponder, Lewis Chodosh, Stephen Johnston and an international editorial board.